Cmxtwenty

CMX Twenty is a biotechnology company dedicated to developing non-opioid therapeutics for the treatment of chronic pain. Founded by researchers from the University of Arizona, the company focuses on small molecule inhibitors that disrupt the interaction between the Collapsing Response Mediator Protein 2 (CRMP2) and the voltage-gated sodium channel NaV1.7. This novel mechanism aims to provide effective pain relief without the addictive properties or side effects associated with traditional opioids. The company's lead program, CMX-020, has demonstrated potential in preclinical models of neuropathic pain. In early 2023, CMX Twenty was acquired by Eli Lilly to bolster their pain management pipeline.